The verdict
Our read at a glance.
Whether CagriSema's combined amylin and GLP-1 approach delivers clearly better weight and metabolic outcomes than its components and leads to approval.
- The signal
- Late-stage trials in the REDEFINE program have tested CagriSema for weight loss in obesity, with results that drew scrutiny over how the combination compares with expectations and with other drugs. As an investigational product, its full benefit and safety are still being established.
- The unknown
- Whether the combination's real-world weight loss and tolerability justify it over single agents and rival dual agonists, and how trial results translate to approval and practice.
- Our read
- A heavily watched investigational obesity combination, not yet approved. CagriSema's two-hormone approach is plausible, but its late-stage results have been debated, so it should be read as investigational until approval and full data.
The mechanism
How it works.
CagriSema pairs two peptides in one weekly injection: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. Cagrilintide acts on amylin receptors in the brainstem to curb appetite and slow gastric emptying, while semaglutide acts on GLP-1 receptors to add its own appetite suppression and glucose-lowering, both of which feed into brain circuits that govern hunger and satiety. The premise is that hitting these two complementary hormone pathways at once produces more appetite reduction and weight loss than either peptide alone, a premise still being tested in late-stage trials since CagriSema is not approved.
Safety & regulatory boundary
The consequential part.
CagriSema is investigational and not an approved product. Its safety profile, including gastrointestinal effects common to amylin and GLP-1 drugs, is still being characterized. It is a specific combination product and is not the same as its individual components or as compounded or research-labeled versions. Its development status does not support use outside trials.
What's next
What we're watching.
Full REDEFINE Phase 3 results, regulatory filings, and comparisons with semaglutide, tirzepatide, and retatrutide.
Context
Why this is discussed.
CagriSema is one of the most-watched next-generation obesity drugs because it combines two complementary appetite hormones, and its trial readouts have drawn heavy attention.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-05-21
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-08-04
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2023-03-01
ClinicalTrials.gov · PHASE1 · COMPLETED · 2024-02-27
ClinicalTrials.gov · PHASE1 · RECRUITING · 2026-04-10
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2022-11-01
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2024-11-05
ClinicalTrials.gov · PHASE3 · COMPLETED · 2024-06-24
Indexed literature (PubMed)12
Yao H et al. · BMJ · 2024
Garvey WT et al. · N Engl J Med · 2025
Kokkorakis M et al. · Pharmacol Rev · 2025
Melson E et al. · Int J Obes (Lond) · 2025
Dutta D et al. · Indian J Endocrinol Metab · 2024
Davies MJ et al. · N Engl J Med · 2025
Mann JFE et al. · Nat Med · 2024
Frias JP et al. · Lancet · 2023
Rubio-Herrera MA et al. · Med Clin (Barc) · 2025
Bianchettin RG et al. · J Am Coll Cardiol · 2023
Son JW et al. · Endocr Rev · 2026
Bailey CJ et al. · Peptides · 2025
Keep reading